RCEL trades 0.5% below Wall Street's consensus target of $11.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RCEL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Avita Medical Inc. (RCEL) has a Wall Street consensus price target of $11.00, based on estimates from 8 covering analysts. With the stock currently trading at $10.95, this represents a potential upside of +0.5%. The company has a market capitalization of $272M.
Analyst price targets range from a low of $10.00 to a high of $12.00, representing a 18% spread in expectations. The median target of $11.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RCEL trades at a trailing P/E of -6.3x. Analysts expect EPS to grow +32.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 XTNTXtant Medical Holdings, Inc. | $53M | $0.38 | — | — | — | — | — |
 TELATELA Bio, Inc. | $58M | $1.30 | — | — | — | — | — |
 MDXGMiMedx Group, Inc. | $695M | $4.77 | $7.67 | +60.8% | Buy | — | 15 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 APYXApyx Medical Corporation | $124M | $2.95 | $7.00 | +137.3% | Buy | — | 9 |
 ANGOAngioDynamics, Inc. | $641M | $15.51 | $19.50 | +25.7% | Hold | — | 11 |
 SYKStryker Corporation | $104.8B | $273.40 | $372.39 | +36.2% | Buy | 18.2x | 52 |
 BSXBoston Scientific Corporation | $66.3B | $44.62 | $66.30 | +48.6% | Buy | 13.6x | 44 |
 ZBHZimmer Biomet Holdings, Inc. | $17.6B | $90.88 | $103.11 | +13.5% | Hold | 10.7x | 42 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
Quick answers to the most common questions about buying RCEL stock.
The consensus price target for RCEL is $11, close to the current price of $10.95 (0.5% implied move). Based on 8 analyst estimates, the stock appears fairly valued near current levels.
RCEL has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $11 implies 0.5% upside from current levels.
RCEL's current price is $10.95 with a consensus target of $11 (0.5% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $12 for RCEL, while the most conservative target is $10. The consensus of $11 represents the median expectation. These targets typically reflect 12-month expectations.
RCEL is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RCEL stock forecast based on 8 Wall Street analysts shows a consensus price target of $11, with estimates ranging from $10 (bear case) to $12 (bull case). The median consensus rating is "Buy".
RCEL appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $11 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RCEL analyst price targets range from $10 to $12, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.